Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 20…

IMA402 PRAME bispecific continues to demonstrate encouraging anti-tumor activity in multiple indications, alongside a ...
quiverquant

Immatics Reports Encouraging ESMO Data for IMA402 and IMA203CD8 Across Multiple PRAME-Positive Cancers

Immatics reports promising anti-tumor activity and safety of IMA402 and IMA203CD8 in advanced cancers, supporting further development.
Psychiatry Advisor

Gamified Digital CBT Intervention May Lower Anxiety in Children

Parent-reported anxiety scores decline significantly in children who complete a gamified digital cognitive behavioral therapy program.
BIOENGINEER

Brain waves reveal cybersickness in real time, UMD study finds

University of Maryland researchers used EEG to identify statistically significant brain wave changes linked to cybersickness ...
BIOENGINEER

Chinese Herbal Medicine for Recurrent UTI: Signals Too Fragile to Trust

A critical review finds that clinical signals for Chinese herbal medicines against recurrent urinary tract infection are ...
Pharmabiz

Merck & Moderna to present positive results from phase 3 INTerpath-001 trial for intismeran autogene plus Keytruda at ESMO 2026 Presidential Symposium

Merck & Moderna to present positive results from phase 3 INTerpath-001 trial for intismeran autogene plus Keytruda at ESMO 2026 Presidential Symposium: Rahway, New Jersey Saturday ...
Stock Titan

Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026

Disease control was 62.2% vs. 36.8%; crossover-adjusted overall survival was not statistically significant (HR 0.85; p=0.53).
Stock Titan

Cumberland Pharmaceuticals Announces ASSIST-SSc Trial Top-Line Results

Cumberland Pharmaceuticals (CPIX) announced top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban in ...